Pregabalin litigation - why did the SPCs lapse?

No items found.
​
31 May 2018
Tags
Life
Table of contents
  • Toc Heading
  • Toc Heading

Writing in the GRUR Newsletter ahead of the decision of the Supreme Court on the validity of a European patent owned by a subsidiary of Pfizer, covering the use of pregabalin in the treatment of pain, Darren Smyth looks at the various theories as to why the related SPCs were allowed to lapse.

Related articles

See all articles

EIP appoints Catherine Howell as Partner, marking the firm’s first home‑grown litigation partner
05 March 2026
EIP is pleased to announce the promotion of Catherine Howell to Partner, marking a significant milestone as she becomes the firm’s first home‑grown litigation partner. Catherine joined EIP as a Trainee Solicitor in 2015 and has progressed through every stage of the firm’s litigation practice, most recently serving as Managing Associate.
​
EIP welcomes Anders Hansson as Partner to further strengthen our digital practice
19 January 2026
EIP is pleased to welcome Anders Hansson as Partner, bringing nearly 20 years of experience in AI, robotics, digital technologies, and European patent strategy. His industry and private‑practice background further strengthens our digital and high‑tech capabilities across Europe.
​
EIP Recognised in The Times Best Law Firms 2026
03 December 2025
EIP is proud to be featured in The Times Best Law Firms 2026, a prestigious list based on peer recommendations across the legal industry. This recognition highlights EIP’s commitment to technical excellence, client-focused service, and innovative IP strategies. From high-value patent litigation to strategic portfolio management, EIP continues to deliver results that matter for clients in technology, life sciences, and engineering. This accolade reinforces our position as a trusted leader in intellectual property law.
​